Belgium-based AI brain imaging company icometrix announced that it has received a CPT-III code from the American Medical Association, allowing for reimbursement of its costs Approved by the FDA Software for MRI quantification of the brain.
icometrix AI-powered quantitative brain analysis software provides metrics for cerebral MRI scans to help physicians diagnose, monitor and assess treatment responses in patients with neurological conditions such as Alzheimer’s and dementia, multiple sclerosis, epilepsy, stroke and Parkinson’s.
The CPT code allows qualified healthcare professionals to report their use of icometrix AI brain imaging software as practice expenses.
THE BIGGER TREND
icometrix receive $18 million funding in 2019 to expand his brain software. The Belgian company received FDA clearance for its icobrain-ctp offering in February 2020.
Last month the company announced She received a grant from the Michael J. Fox Foundation to research brain MRI biomarkers for Parkinson’s disease in collaboration with a professor of neurology and neurological sciences at Stanford Medicine.
March, icometrix received £1,417,658 ($1,798,944) National Institute for Health and Care Research grant to accelerate research in multiple sclerosis imaging.
Another company using AI software to help providers diagnose brain disorders is a South Korean health technology company neurophet. In April, the company received certification from the Health Sciences Authority in Singapore for its AI-based assistance software for the diagnosis of degenerative brain diseases.
